SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3202 131 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Incyte markets the first JAK inhibitor approved for any use, Jakafi (ruxolitinib). Add an interesting pipeline, and INCY is fun to follow, if not own. Please contribute, and good luck!
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3202"Pfizer drops 10 mg dose of best-selling Xeljanz...." endpts.comscaram(o)uche-2/20/2019
3201INCY calls very active on GS upgrade. Where were they when INCY was at ~$55?Miljenko Zuanic-1/15/2019
3200INCY is bit better than MGNX in dealing with China, still far from "brilliaMiljenko Zuanic-12/17/2018
3199With ongoing carnage in bio-sector, INCY is not spared. 3Q results ( finance.yahMiljenko Zuanic-10/30/2018
3198Dose levels, 13.5 mg for Pem v 300 mg for 087,...is whole story. To be active caMiljenko Zuanic-10/21/2018
3197here you go, tuck. 1) Primary bile duct cancer is uncommon in the United Statessoftware salesperson-10/21/2018
3196No chatter here on the FGFR inhibitor. Data that superficially looks better thatuck-10/21/2018
319510% discontinuation rate is not that bad, ....but it is not "good" as Miljenko Zuanic-10/19/2018
3194INC280 Capmanitib at ESMO: INC280 ESMO Some slides regarding SAEs. INC280 Etuck-10/19/2018
3193There was leak of this news 3 days ago, spike in INCY price from "nowhere&qMiljenko Zuanic-9/27/2018
3192Andy Biotech? @AndyBiotech8m8 minutes ago More $GERN Imetelstat data metamorphscaram(o)uche-9/27/2018
3191bloodjournal.org < In an age- and sex-matched control group with none or conMiljenko Zuanic-6/15/2018
3190hematology.org >> They also speculate that screening for a preexisting B-scaram(o)uche-6/15/2018
3189Tuck, I was bit sarcastic. That is all! Herve is well aware that Epa is "mMiljenko Zuanic-5/11/2018
3188What do you mean? He bought near $60 like you (and me, via sold puts as usual).tuck-5/11/2018
3187Is Herve damn?? secfilings.nasdaq.comMiljenko Zuanic-5/10/2018
3186Thnx. Overall, street view/see Ruxo success in acute/chronic GVHD. They need somMiljenko Zuanic-5/5/2018
3185cool..... bloodjournal.org >> Topical ruxolitinib, unlike corticosterscaram(o)uche-5/4/2018
3184OT, again >> Look at the daily chart for qure and once versus that for sgscaram(o)uche-4/24/2018
3183>> now playing with gains << Cool. House money, nothing feels bettscaram(o)uche-4/24/2018
3182RE:VKTX "force selling"---> it may be!? Secondary @5 was OK, nothinMiljenko Zuanic-4/24/2018
3181So you bought after the disaster, and believe Epa still lives? Interesting, hopscaram(o)uche-4/24/2018
3180Because of the good safety, I would bump dose to 300mg/day and continue to combiMiljenko Zuanic-4/24/2018
3179believe that Epa is not dead Which remaining combos(s) are of interest? Edit: Ttuck-4/24/2018
3178<How could any FDA be more liberal than the Gottlieb FDA?> They (reviewerMiljenko Zuanic-4/24/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2024 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News